89 related articles for article (PubMed ID: 20153188)
1. Structure-activity relationships of norepinephrine reuptake inhibitors with benzothiadiazine dioxide or dihydrosulfostyril cores.
Fensome A; Goldberg J; McComas CC; Trybulski EJ; Woodworth RP; Deecher DC; Whiteside GT; Zhang P
Bioorg Med Chem Lett; 2010 Mar; 20(5):1555-8. PubMed ID: 20153188
[TBL] [Abstract][Full Text] [Related]
2. Structure-activity relationships of chiral selective norepinephrine reuptake inhibitors (sNRI) with increased oxidative stability.
Hudson S; Kiankarimi M; Eccles W; Dwight W; Mostofi YS; Genicot MJ; Fleck BA; Gogas K; Aparicio A; Wang H; Wen J; Wade WS
Bioorg Med Chem Lett; 2008 Aug; 18(16):4491-4. PubMed ID: 18672364
[TBL] [Abstract][Full Text] [Related]
3. Discovery of novel selective norepinephrine reuptake inhibitors: 4-[3-aryl-2,2-dioxido-2,1,3-benzothiadiazol-1(3H)-yl]-1-(methylamino)butan-2-ols (WYE-103231).
O'Neill DJ; Adedoyin A; Alfinito PD; Bray JA; Cosmi S; Deecher DC; Fensome A; Harrison J; Leventhal L; Mann C; McComas CC; Sullivan NR; Spangler TB; Uveges AJ; Trybulski EJ; Whiteside GT; Zhang P
J Med Chem; 2010 Jun; 53(11):4511-21. PubMed ID: 20462211
[TBL] [Abstract][Full Text] [Related]
4. Biaryl analogues of conformationally constrained tricyclic tropanes as potent and selective norepinephrine reuptake inhibitors: synthesis and evaluation of their uptake inhibition at monoamine transporter sites.
Zhou J; Zhang A; Kläss T; Johnson KM; Wang CZ; Ye YP; Kozikowski AP
J Med Chem; 2003 May; 46(10):1997-2007. PubMed ID: 12723962
[TBL] [Abstract][Full Text] [Related]
5. 1- or 3-(3-Amino-2-hydroxy-1-phenyl propyl)-1,3-dihydro-2H-benzimidazol-2-ones: potent, selective, and orally efficacious norepinephrine reuptake inhibitors.
Zhang P; Terefenko EA; Bray J; Deecher D; Fensome A; Harrison J; Kim C; Koury E; Mark L; McComas CC; Mugford CA; Trybulski EJ; Vu AT; Whiteside GT; Mahaney PE
J Med Chem; 2009 Sep; 52(18):5703-11. PubMed ID: 19722525
[TBL] [Abstract][Full Text] [Related]
6. Design, synthesis and evaluation of N-[(3S)-pyrrolidin-3-yl]benzamides as selective noradrenaline reuptake inhibitors: CNS penetration in a more polar template.
Fish PV; Wakenhut F; Ryckmans T; Stobie A
Bioorg Med Chem Lett; 2009 Aug; 19(16):4579-83. PubMed ID: 19616432
[TBL] [Abstract][Full Text] [Related]
7. Discovery of a new series of monoamine reuptake inhibitors, the 1-amino-3-(1H-indol-1-yl)-3-phenylpropan-2-ols.
Kim CY; Mahaney PE; McConnell O; Zhang Y; Manas E; Ho DM; Deecher DC; Trybulski EJ
Bioorg Med Chem Lett; 2009 Sep; 19(17):5029-32. PubMed ID: 19632110
[TBL] [Abstract][Full Text] [Related]
8. New fluorinated 1,2,4-benzothiadiazine 1,1-dioxides: discovery of an orally active cognitive enhancer acting through potentiation of the 2-amino-3-(3-hydroxy-5-methylisoxazol-4-yl)propionic acid receptors.
Francotte P; Goffin E; Fraikin P; Lestage P; Van Heugen JC; Gillotin F; Danober L; Thomas JY; Chiap P; Caignard DH; Pirotte B; de Tullio P
J Med Chem; 2010 Feb; 53(4):1700-11. PubMed ID: 20108934
[TBL] [Abstract][Full Text] [Related]
9. Structure-activity relationships of the cycloalkanol ethylamine scaffold: discovery of selective norepinephrine reuptake inhibitors.
Mahaney PE; Gavrin LK; Trybulski EJ; Stack GP; Vu TA; Cohn ST; Ye F; Belardi JK; Santilli AA; Sabatucci JP; Leiter J; Johnston GH; Bray JA; Burroughs KD; Cosmi SA; Leventhal L; Koury EJ; Zhang Y; Mugford CA; Ho DM; Rosenzweig-Lipson SJ; Platt B; Smith VA; Deecher DC
J Med Chem; 2008 Jul; 51(13):4038-49. PubMed ID: 18557608
[TBL] [Abstract][Full Text] [Related]
10. Discovery of a potent, selective, and less flexible selective norepinephrine reuptake inhibitor (sNRI).
Wu D; Pontillo J; Ching B; Hudson S; Gao Y; Fleck BA; Gogas K; Wade WS
Bioorg Med Chem Lett; 2008 Jul; 18(14):4224-7. PubMed ID: 18550369
[TBL] [Abstract][Full Text] [Related]
11. Design and synthesis of reboxetine analogs morpholine derivatives as selective norepinephrine reuptake inhibitors.
Xu W; Gray DL; Glase SA; Barta NS
Bioorg Med Chem Lett; 2008 Oct; 18(20):5550-3. PubMed ID: 18805691
[TBL] [Abstract][Full Text] [Related]
12. Structure-activity relationships of the 1-amino-3-(1H-indol-1-yl)-3-phenylpropan-2-ol series of monoamine reuptake inhibitors.
Mahaney PE; Kim CY; Coghlan RD; Cohn ST; Heffernan GD; Huselton CA; Terefenko EA; Vu AT; Zhang P; Burroughs KD; Cosmi SA; Bray JA; Johnston GH; Deecher DC; Trybulski EJ
Bioorg Med Chem Lett; 2009 Oct; 19(19):5807-10. PubMed ID: 19713106
[TBL] [Abstract][Full Text] [Related]
13. 1-(Indolin-1-yl)-1-phenyl-3-propan-2-olamines as potent and selective norepinephrine reuptake inhibitors.
Vu AT; Cohn ST; Zhang P; Kim CY; Mahaney PE; Bray JA; Johnston GH; Koury EJ; Cosmi SA; Deecher DC; Smith VA; Harrison JE; Leventhal L; Whiteside GT; Kennedy JD; Trybulski EJ
J Med Chem; 2010 Mar; 53(5):2051-62. PubMed ID: 20131864
[TBL] [Abstract][Full Text] [Related]
14. Design, synthesis, and pharmacological evaluation of phenoxy pyridyl derivatives as dual norepinephrine reuptake inhibitors and 5-HT1A partial agonists.
Dounay AB; Barta NS; Campbell BM; Coleman C; Collantes EM; Denny L; Dutta S; Gray DL; Hou D; Iyer R; Maiti SN; Ortwine DF; Probert A; Stratman NC; Subedi R; Whisman T; Xu W; Zoski K
Bioorg Med Chem Lett; 2010 Feb; 20(3):1114-7. PubMed ID: 20031410
[TBL] [Abstract][Full Text] [Related]
15. Acetic acid derivatives of 3,4-dihydro-2H-1,2,4-benzothiadiazine 1,1-dioxide as a novel class of potent aldose reductase inhibitors.
Chen X; Zhu C; Guo F; Qiu X; Yang Y; Zhang S; He M; Parveen S; Jing C; Li Y; Ma B
J Med Chem; 2010 Dec; 53(23):8330-44. PubMed ID: 21062005
[TBL] [Abstract][Full Text] [Related]
16. Further structural exploration of trisubstituted asymmetric pyran derivatives (2S,4R,5R)-2-benzhydryl-5-benzylamino-tetrahydropyran-4-ol and their corresponding disubstituted (3S,6S) pyran derivatives: a proposed pharmacophore model for high-affinity interaction with the dopamine, serotonin, and norepinephrine transporters.
Zhang S; Fernandez F; Hazeldine S; Deschamps J; Zhen J; Reith ME; Dutta AK
J Med Chem; 2006 Jul; 49(14):4239-47. PubMed ID: 16821783
[TBL] [Abstract][Full Text] [Related]
17. Design, synthesis, and pharmacology of novel 7-substituted 3,4-dihydro-2H-1,2,4-benzothiadiazine 1,1-dioxides as positive allosteric modulators of AMPA receptors.
Francotte P; Tullio Pd; Goffin E; Dintilhac G; Graindorge E; Fraikin P; Lestage P; Danober L; Thomas JY; Caignard DH; Pirotte B
J Med Chem; 2007 Jun; 50(13):3153-7. PubMed ID: 17552506
[TBL] [Abstract][Full Text] [Related]
18. Discovery of novel selective norepinephrine inhibitors: 1-(2-morpholin-2-ylethyl)-3-aryl-1,3-dihydro-2,1,3-benzothiadiazole 2,2-dioxides (WYE-114152).
O'Neill DJ; Adedoyin A; Bray JA; Deecher DC; Fensome A; Goldberg JA; Harrison J; Leventhal L; Mann C; Mark L; Nogle L; Sullivan NR; Spangler TB; Terefenko EA; Trybulski EJ; Uveges AJ; Vu A; Whiteside GT; Zhang P
J Med Chem; 2011 Oct; 54(19):6824-31. PubMed ID: 21916421
[TBL] [Abstract][Full Text] [Related]
19. Synthesis and anti-HIV-1 activity of a novel series of 1,4,2-benzodithiazine-dioxides.
Brzozowski Z; Saczewski F; Neamati N
Bioorg Med Chem Lett; 2006 Oct; 16(20):5298-302. PubMed ID: 16908143
[TBL] [Abstract][Full Text] [Related]
20. 1-(Aryl)-6-[alkoxyalkyl]-3-azabicyclo[3.1.0]hexanes and 6-(aryl)-6-[alkoxyalkyl]-3-azabicyclo[3.1.0]hexanes: a new series of potent and selective triple reuptake inhibitors.
Micheli F; Cavanni P; Arban R; Benedetti R; Bertani B; Bettati M; Bettelini L; Bonanomi G; Braggio S; Checchia A; Davalli S; Di Fabio R; Fazzolari E; Fontana S; Marchioro C; Minick D; Negri M; Oliosi B; Read KD; Sartori I; Tedesco G; Tarsi L; Terreni S; Visentini F; Zocchi A; Zonzini L
J Med Chem; 2010 Mar; 53(6):2534-51. PubMed ID: 20170186
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
